Here are the 10-K annual reports from Ainos, Inc. Warrants (AIMDW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AIMDW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AIMDW filings page.
Ainos, Inc. outlines its dual strategy of commercializing its AI-based scent digitization platform, AI Nose, and advancing its low-dose oral interferon program, VELDONA, while warning of ongoing losses and heavy funding needs. AI Nose targets healthcare and industrial applications, including semiconductor manufacturing, through hardware sales and subscription deployments. VELDONA has completed extensive human and animal studies and holds orphan drug designation for oral warts in HIV-seropositive patients, but none of the human or veterinary drug candidates are yet approved. The company reports minimal 2025 revenue, operating losses of about $14 million, cumulative losses above $67 million, cash of roughly $417 thousand, and emphasizes material dependence on new capital to continue operations.